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Abstract
The N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine may have rapid, albeit tran-
sient, antidepressant properties. This study in patients with treatment-resistant major depression (TRD)
aimed to (1) replicate the acute eﬃcacy of single-dose intravenous (i.v.) ketamine; (2) test the eﬃcacy of the
glutamate-modulating agent riluzole in preventing post-ketamine relapse ; and (3) examine whether pre-
treatment with lamotrigine would attenuate ketamine’s psychotomimetic eﬀects and enhance its anti-
depressant activity. Twenty-six medication-free patients received open-label i.v. ketamine (0.5 mg/kg
over 40 min). Two hours prior to infusion, patients were randomized to lamotrigine (300 mg) or placebo.
Seventeen patients (65%) met response criterion (o50% reduction from baseline on the Montgomery–
Asberg Depression Rating Scale) 24 h following ketamine. Lamotrigine failed to attenuate the mild, tran-
sient side-eﬀects associated with ketamine and did not enhance its antidepressant eﬀects. Fourteen
patients (54%) met response criterion 72 h following ketamine and proceeded to participate in a 32-d,
randomized, double-blind, placebo-controlled, ﬂexible-dose continuation trial of riluzole (100–200 mg/d).
The main outcome measure was time-to-relapse. An interim analysis found no signiﬁcant diﬀerences in
time-to-relapse between riluzole and placebo groups [log-rank x2=0.17, d.f.=1, p=0.68], with 80%
of patients relapsing on riluzole vs. 50% on placebo. The trial was thus stopped for futility. This pilot
study showed that a sub-anaesthetic dose of i.v. ketamine is well-tolerated in TRD, and may have rapid
and sustained antidepressant properties. Riluzole did not prevent relapse in the ﬁrst month following
ketamine. Further investigation of relapse prevention strategies post-ketamine is necessary.
Received 22 September 2008 ; Reviewed 19 December 2008 ; Revised 22 December 2008 ; Accepted 3 February 2009 ;
First published online 17 March 2009
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Introduction
Safe and eﬀective therapies with rapid onset of action
for treatment-resistant major depression (TRD) are
needed (Machado-Viera et al. 2008). The glutamatergic
system may oﬀer a rational, disease-modifying target
for drug development for severe mood disorders
(Sanacora et al. 2008). Ketamine is a non-competitive,
high-aﬃnity N-methyl-D-aspartate (NMDA) gluta-
mate receptor antagonist used as an anaesthetic and
analgesic agent for many years, and investigated as a
probe of NMDA receptor function relevant to psy-
chotic, cognitive, and alcohol use disorders (Deakin
et al. 2008; Honey et al. 2008 ; Krystal et al. 2005 ; Lahti
et al. 1995 ; Petrakis et al. 2004). A growing body of
translational research on ketamine has demonstrated
antidepressant-like eﬀects in forced swimming,
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learned helplessness, passive avoidance, and tail sus-
pension tests (Chaturvedi et al. 2001 ; Garcia et al. 2008;
Maeng et al. 2008 ; Mantovani et al. 2003; Yilmaz et al.
2002). Two published clinical trials in medication-
free hospitalized patients with major depressive dis-
order have demonstrated the eﬃcacy of a single
sub-anaesthestic dose of intravenous (i.v.) ketamine
(0.5 mg/kg over 40 min) using identical placebo-
controlled, double-blind, cross-over designs (Berman
et al. 2000 ; Zarate et al. 2006). In both studies, detect-
able antidepressant responses occurred within several
hours, and y50% of patients met response criteria
72 h following i.v. ketamine. Several patients sus-
tained their response for more than 1 wk – a ﬁnding
unexplained by ketamine’s short elimination half-life
(2–3 h). Transient psychotomimetic side-eﬀects nor-
malized within 2 h of infusion in all patients (Berman
et al. 2000 ; Zarate et al. 2006).
Continuation therapy following acute remission of
depressive symptoms is the standard of practice due to
high risk of relapse, particularly for pharmacotherapy-
resistant patients (Rush et al. 2006a ; Sackeim et al.
1990, 2001). For example, relapse rates for depressed
patients in remission following electroconvulsive
therapy (ECT) are extremely high despite vigorous
continuation pharmacotherapy (Sackeim et al. 2001) or
continuation ECT (Kellner et al. 2006), with the greatest
risk of relapse occurring within the ﬁrst month.
Themajor objective of the present studywas to test a
novel pharmacological strategy for relapse prevention
after acute ketamine administration with a random-
ized,double-blind,placebo-controlledcontinuation trial.
Riluzole, a glutamate-modulating agent with neuro-
protective properties initially approved for amyotro-
phic lateral sclerosis (ALS), was chosen. First, we
hypothesized that a mechanistic synergy between
ketamine and riluzole might confer protection against
relapse. While ketamine’s primary site of action is at
the phencyclidine site within the ionotropic channel
of the NMDA receptor, ketamine also increases pre-
synaptic release of glutamate (Maeng et al. 2008;
Moghaddam et al. 1997), resulting in enhanced gluta-
mate throughput via ionotropic a-amino-3-hydroxy-5-
methyl-isoxazole-4-propionic acid (AMPA) receptors.
An immediate increase in AMPA-to-NMDA receptor
function may be critical to ketamine’s rapid anti-
depressant activity (Maeng et al. 2008 ; Maeng &
Zarate, 2008). Although not a direct NMDA receptor
antagonist, riluzole also has multiple eﬀects on the
ionotropic glutamate receptor system, including en-
hancement of synaptic AMPA receptor expression (Du
et al. 2007) and blockade of NMDA receptor activation
(Kalia et al. 2008 ; Pittenger et al. 2008). Ketamine
administered to rats at a dose that induces antidep-
ressant-like eﬀects increased levels of brain-derived
neurotrophic factor (BDNF) in the hippocampus
(Garcia et al. 2008). Chronic riluzole administration has
also been associated with enhancement of BDNF and
other neurotrophic growth factors (Fumagalli et al.
2006 ; Katoh-Semba et al. 2002; Mizuta et al. 2001), and
was found to increase levels of hippocampal N-acetyl-
aspartate (Mathew et al. 2008a), a neuronal marker
linked to BDNF expression (Egan et al. 2003 ; Stern et al.
2008). Second, three open-label studies have shown
that riluzole was potentially eﬀective as monotherapy
or adjunctive therapy in TRD or bipolar depression
(Sanacora et al. 2007 ; Zarate et al. 2004, 2005) and was
as well-tolerated as in ALS patients (Miller et al. 2007).
Third, riluzole has a rapid dosage titration; the thera-
peutic eﬀect is achieved with a dose of 100 mg/d on
the ﬁrst day.
Additional aims were to replicate previous reports
of the rapid and sustained antidepressant eﬀects of
i.v. ketamine, to investigate ketamine’s eﬃcacy in
the outpatient setting, and to test a method for opti-
mizing the safe and eﬀective delivery of i.v. ketamine.
In a study of healthy volunteers (Anand et al. 2000),
lamotrigine (300 mg) given 2 h prior to i.v. ketamine
increased the immediate mood-elevating eﬀects of
ketamine while attenuating its acute psychotomimetic
and cognitive eﬀects (Anand et al. 2000). We employed
the same method in the present study.
Method
Study overview
This two-phase study was conducted between
December 2006 and July 2008 at the Mount Sinai
School of Medicine (MSSM), an academic medical
centre. Phase 1 consisted of : (1) 2-wk psychotropic
medication washout period (4 wk for ﬂuoxetine) ;
(2) 24-h admission to the General Clinical Research
Center (GCRC) for randomized, double-blind pre-
treatment with a single dose of lamotrigine (300 mg
p.o.) or placebo, followed by open-label i.v. ketamine
(0.5 mg/kg over 40 min) and serial assessments ; and
(3) for 24-h responders (see below), 48-h and 72-h post-
ketamine outpatient visits. Patients who continued
to meet response criteria at 72-h post-ketamine were
eligible for phase 2, a 32-d, randomized, double-blind,
ﬂexible-dose continuation trial of riluzole (100–
200 mg/d) or placebo. The study was approved by the
MSSM Institutional Review Board, in accordance with
the principles of the Declaration of Helsinki. Patients
provided written informed consent prior to partici-
pation.
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Study participants
Patients (aged 21–70 yr) were either receiving psychi-
atric care at screening or were previously under the
care of a psychiatrist. Diagnoses were made using the
Structured Clinical Interview for DSM-IV – Patient Ed-
ition (First et al. 2001), performed by an experienced
research clinician with an independent interview by a
psychiatrist. A diagnosis of major depressive disorder,
chronic and/or recurrent, was required, of at least
moderate severity, determined by screening and pre-
ketamine baseline scores of o32 on the Inventory of
Depressive Symptomatology – Clinician Rated (IDS-
C30 ; Rush et al. 1996). Patients needed to have
demonstrated insuﬃcient response to o2 adequate
antidepressant trials in the current episode, according
to Antidepressant Treatment History Form (ATHF)
criteria (Sackeim, 2001). Patients were excluded if
they had current psychotic symptoms; had lifetime
histories of bipolar disorder, schizophrenia, or schizo-
aﬀective disorder ; had current anorexia or bulimia
nervosa ; had alcohol or drug abuse within the past
6 months ; or had any unstable medical or neurologi-
cal illness that increased the risks of ketamine admin-
istration. Physical examination, vital signs, weight,
ECG, standard blood tests (including liver function
tests) and urinalysis conﬁrmed absence of unstable
medical illnesses. Urine toxicology and hCG tests
conﬁrmed absence of recent illicit substances use and
pregnancy, respectively. Participants who reported
lifetime use of ketamine, PCP, or riluzole were ex-
cluded.
Randomization and masking procedures
Patients who met enrolment criteria for phase 1 were
randomly allocated to lamotrigine or placebo by a
permuted block procedure consisting of blocks of two
or four patients. The randomization list was created by
a biostatistician with no patient contact. Based on this
list, the MSSM pharmacy distributed to the GCRC for
each patient three capsules (100 mg lamotrigine each
or placebo) identical in size, weight, appearance, and
taste. A separate randomization list for allocation to
riluzole or placebo was created in a similar fashion
for phase 2 participants. All study investigators, staﬀ,
and patients were masked to pretreatment (lamo-
trigine/placebo) and continuation group (riluzole/
placebo) assignment.
Study design
Patients arrived at the GCRC at 07 :30 hours after an
overnight fast. Repeat urine tests (toxicology and, if
applicable, pregnancy) were performed upon arrival.
All procedures were performed in a private, quiet
room with muted lighting. Following baseline ratings,
2 h prior to i.v. ketamine infusion, patients received
300 mg lamotrigine or placebo by mouth. Lamotrigine
levels have been demonstrated to peak 1–4 h following
oral administration (Hamilton et al. 1993). Repeat rat-
ings were performed 1 h prior to ketamine infusion.
An indwelling catheter was then placed in the ante-
cubital vein of the non-dominant arm, and pulse (P),
non-invasive blood pressure (BP), digital pulse-
oximetry, and ECG monitoring were instituted. Nasal
cannula oxygen was administered with side-stream
capnometry monitoring. Physiological monitoring
data were recorded on a standard anaesthesia record
beginning 5 min prior to infusion.
Racemic ketamine hydrochloride (Bedford Labora-
tories, USA) 0.5 mg/kg diluted in normal saline was
administered over 40 min by i.v. infusion pump be-
ginning 2 h after lamotrigine/placebo ingestion. An
anaesthesiologist was present throughout the infu-
sion. Following a 4-h post-infusion monitoring period,
patients were given a meal and remained overnight at
the GCRC with regular assessment of clinical status
and vital signs by nursing staﬀ.
Patients completed an outcome expectancy rating
on a 5-point Likert scale (1=no improvement, 5=full
recovery) at baseline. Mood ratings were conducted at
baseline (pre- and post-lamotrigine/placebo pretreat-
ment), at 40, 120, 180 and 240 min following the
start of the i.v. infusion, and at 24-, 48- and 72-h
post-ketamine, and included the Montgomery–Asberg
Depression Rating Scale (MADRS; Montgomery &
Asberg, 1979) and item 1 of the Young Mania Rating
Scale (YMRS; Young et al. 1978). Patients completed
the Quick Inventory of Depressive Symptomatology –
Self-Report (QIDS-SR16 ; Rush et al. 2003) at these
same time- points. For repeated MADRS and QIDS-SR
assessments on the day of infusion, scores for items
related to sleep and appetite were carried forward
from baseline. Psychotomimetic side-eﬀects were
evaluated at regular intervals for 4 h from the start of
infusion with the Brief Psychiatric Rating Scale (BPRS;
Overall & Gorham, 1962) positive symptoms subscale
(four items: conceptual disorganization, hallucina-
tions, suspiciousness, and unusual thought content),
the Clinician-Administered Dissociative States Scale
(CADSS; Bremner et al. 1998), and a visual analog
scale (VAS) for subjective ‘high’ (Petrakis et al. 2004).
Side-eﬀects throughout the study were recorded with
the Systematic Assessment for Treatment Emergent
Eﬀects (SAFTEE-SI ; NIMH, 1986). Raters were indi-
viduals with graduate degrees and extensive training
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who achieved high inter-rater reliability for the
MADRS [intra-class correlation coeﬃcient (ICC)=0.96]
and BPRS-positive symptoms subscale (ICC=0.97).
Response, deﬁned as o50% reduction in MADRS
score at 24 h relative to the previous day’s baseline,
with minimal reported/apparent sad mood (f2) on
items 1 and 2, was the initial primary eﬃcacy measure,
and determined eligibility for continued study par-
ticipation. Remission was deﬁned as MADRS f9.
Participants were asked to guess their pretreatment
arm assignment at the 24-h assessment. After a
physical examination, patients were then discharged
home with car service. Non-responders were exited
and treated openly by a study psychiatrist. Initial re-
sponders were instructed to abstain from taking any
psychotropic medications, were reassessed at 48 h
at the outpatient clinic, and, if they continued to
meet response criterion, reassessed 72 h post-infusion.
Relapsers at the 48-h and 72-h visits were exited and
treated openly.
For continuation trial eligibility, patients had to
demonstrate durable response or remission for 72 h,
with a maximum allowable MADRS score of 15 at the
24-, 48- and 72-h assessments. At the 72-h visit, fol-
lowing blood draw for liver function tests and physi-
cal examination, patients were randomized to one of
two continuation pharmacotherapy groups, receiving
either two capsules of riluzole 50 mg each (100 mg/d)
or matching pill placebo under double-blind condi-
tions. Concomitant psychotropic medications were
proscribed. Twice-weekly study visits were conducted
at the outpatient clinic at 3- to 4-d intervals for up to
32 d. Eﬃcacy (MADRS, QIDS-SR16) and safety assess-
ments (vital signs, weight, SAFTEE-SI) were per-
formed at each visit, and medication compliance was
monitored by pill count. Clinical ratings during phase
2 were conducted by the same rater as in phase 1.
A blinded study psychiatrist adjusted riluzole/
placebo dose based on tolerability and Clinical Global
Impression – Improvement (CGI-I ; Guy, 1976) ratings.
Dosing was initiated at 100 mg/d (50 mg b.i.d). At any
visit, if CGI-I showed worsening (score >4), dosage
was ﬂexibly increased to a maximum of 200 mg/d, in
increments of 50 mg/visit.
Time-to-relapse was the main outcome measure,
denoted by: (1) MADRS score of o20 for two con-
secutive visits ; (2) minimum absolute increase of
MADRSo10 points for two consecutive visits relative
to phase 2 baseline ; and (3) meeting modiﬁed DSM-
IV-TR diagnostic criteria for a major depressive epi-
sode (Rush et al. 2006b). At relapse visit or at the end
of trial, repeat laboratory testing was performed. All
participants were oﬀered follow-up care or were
referred back to their psychiatrist upon study com-
pletion.
Statistical analyses
Clinical and demographic features of randomized
groups and comparisons of phase 2 participants with
non-participants were performed using t tests for
continuous measures and Fisher’s exact tests for di-
chotomous variables. Phase 1 eﬃcacy data for MADRS
and QIDS-SR were assessed by analysis of covariance
(ANCOVA), with baseline score as a covariate, and
pretreatment group (lamotrigine, placebo) as the in-
dependent variable. Time-to-relapse in phase 2 was
compared across the riluzole and placebo groups with
the Kaplan–Meier method and log-rank test. Safety
analyses were considered post-hoc and exploratory.
For day-of-infusion psychotomimetic eﬀects, repeated-
measures ANCOVA was performed, with pretreat-
ment drug (two levels) as between-subject factor, time
as repeated-measures factor, and the 60-min rating as
a covariate. Follow-up ANCOVA analyses were con-
ducted at speciﬁed time-points of interest. Random-
ized treatment groups in both study phases were
compared in rates of each side-eﬀect assessed by
SAFTEE-SI, without formal statistical testing.
Twenty-ﬁve patients per continuation pharmaco-
therapy group were required to provide 80% power
(experiment-wise a of 0.05) to detect a signiﬁcant
advantage in relapse time for riluzole vs. placebo, as-
suming 90% relapse for placebo and 50% relapse for
riluzole. We estimated 100 patients would comprise
the intent-to-treat sample in phase 1 (50 per pretreat-
ment group), based on previous ketamine response
durability data (Zarate et al. 2006). This sample size
yielded >80% power to detect a 20% response rate
diﬀerence between pretreatment groups at 24 h (two-
tailed a=0.05, ICC=0.40). Size of actual treatment
eﬀects was calculated with Cohen’s d. All statistical
tests were two-tailed, with signiﬁcance set at p<0.05.




Eligibility assessments were performed for 124 poten-
tial participants (Fig. 1). The intent-to-treat sample
(n=26) was recruited from media/internet advertis-
ing (n=14), psychiatrist referral (n=8), or self-referral
from the New York Mood Disorders Support Group
(n=4). Table 1 presents their demographic and clini-
cal characteristics. Patients had marked depressive
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severity, chronicity, and anxiety comorbidity, and
were highly pharmacotherapy-resistant. Four patients
had previous treatment with ECT. One patient had
received treatment with vagus nerve stimulation (the
device was turned oﬀ during the study) and had
previously participated in a trial of deep brain stimu-
lation. There were no statistically signiﬁcant baseline
diﬀerences between lamotrigine and placebo pretreat-
ment groups.
Phase 1 eﬃcacy outcomes
At the initial eﬃcacy endpoint of 24 h, the overall
reduction in MADRS score was 22.1¡13.0 (t=x8.63,
d.f.=25, p<0.001), with an average improvement of
60¡32%, representing a very large eﬀect size (d=2.11,
95% CI 1.25–2.97). At the 24-h rating, 17/26 patients
(65%) met MADRS response criteria and 13 patients
(50%) met remission criteria (Fig. 2). At the 48-h rat-
ing, 14 patients (54%) maintained their response and
13 patients (50%) met remission criteria ; the same
response and remission rates were observed at 72-h.
Very large reductions in QIDS-SR16 scores were also
found at 24 h (11.4¡6.2, t=9.30, d.f.=25, p<0.001,
d=2.22, 95% CI 1.42–2.23), an average improvement
of 62%¡28. Response and remission rates at 24-h
and 72-h assessed by QIDS-SR16 were consistent with
MADRS (Fig. 2).
Onset of response generally occurred in the initial
4 h (240 min) following i.v. ketamine. Twelve patients
(46%) met MADRS response criteria by 120 min, and
16 patients (62%) met response criteria at 240 min.
Response at 240 min strongly predicted 24-h outcome:
two responders at 240 min failed to maintain response
at 24 h, while three non-responders at 240 min sub-
sequently met response criteria at 24 h. Exploratory
analyses of individual MADRS items at 24 h revealed
that all 10 items improved from baseline, with lassi-
tude showing the largest eﬀect size (d=1.98, 95%
CI 1.25–2.71).
Lamotrigine and placebo pretreatment groups
did not diﬀer in any eﬃcacy measure at the 24-, 48-, or
72-h rating (smallest p=0.38). We did not detect dif-
ferences in MADRS scores between groups 240-min
post-ketamine (lamotrigine 16.3¡12.9 vs. placebo




• Lamotrigine pretreatment (n = 13)
• Placebo pretreatment (n = 13) 
• Did not meet inclusion criteria (n = 46)
• Declined to participate (n = 49) 
Enrolled in Phase 1
ketamine infusion (n = 26)
Enrolled in Phase 2
continuation study
 (n = 14)
Randomized to
riluzole





Discontinued (n = 1)
• Withdrew consent Discontinued (n = 0)
Randomized to
placebo
 (n = 8)
Excluded (n = 95)
• Non-responder at 24 hr  (n = 9)
• Non-responder at 48 hr  (n = 3)
• Non-responder at 72 hr  (n = 0)
Exited due to non-response (n = 12)
Fig. 1. Flow diagram of patient enrolment.
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Phase 1 psychotomimetic side-eﬀects
No patients reported frank positive psychotic symp-
toms or symptoms consistent with formal thought
disorder. Twenty-three of 26 (89%) patients had neg-
ligible changes in BPRS positive symptom subscale
scores over the 240-min post-ketamine period, evi-
denced by decreased (n=6), no change (n=13), or a
1-point peak increase (n=4) in baseline scores (three
patients had peak increases ranging from 3–5 points].
There were no diﬀerences between lamotrigine and
placebo groups in peak change on BPRS positive
symptoms subscale (F=0.20, d.f.=1, 23, p=0.66).
CADSS scores were clustered into low (0–2), medium
(3–10), high (11–25), or very high (o26), restricting
analyses to the 40-min post-ketamine time-point
(Petrakis et al. 2004). Lamotrigine and placebo groups
did not diﬀer in mean CADSS scores at 40 min
(F=0.63, d.f.=1, 24, p=0.80), and did not diﬀer in the
proportion of patients with high (11–25) or very high
(o26) CADSS scores [placebo 4/13 (31%) vs. lamo-
trigine 3/13 (23%) ; Fisher’s exact test p>0.99].
The lamotrigine group reported signiﬁcantly elevated
‘high’ on the VAS only at 40 min; the placebo group
did not (lamotrigine 5.15¡3.95, placebo 2.00¡2.79 ;
p=0.02, 95% CI 0.71–5.92). For YMRS item 1, there
was a signiﬁcant main eﬀect of time (F=3.31, d.f.=4,
20, p=0.03), with no main eﬀect of pretreatment group
(F=2.53, d.f.=1, 23, p=0.13), or grouprtime eﬀects
(F=0.62, d.f.=4, 20, p=0.66).
Phase 2 continuation trial of riluzole
Continuation trial participants (n=14) did not diﬀer
from non-participants (n=12) in any clinical or demo-
graphic variable in Table 1, except for years of edu-
cation (14.0¡2.4 yr vs. 16.5¡2.5 yr; t=2.6, d.f.=24,
p=0.02). Riluzole and placebo groups were compar-
able in age, sex, treatment resistance, pretreatment
randomization, phase 1 baseline MADRS score, phase
1 response/remission rates, and phase 2 baseline
MADRS scores (Supplementary Table S1, online). One
patient dropped out before completing 32 d without
meeting relapse criteria. This patient withdrew con-
sent after the 24-d visit for personal reasons (was
randomized to riluzole and met remission criteria at
exit). The probability of relapse was evaluated using
survival analysis (Fig. 3). Eight of 13 (62%) study
completers relapsed. There were no continuation
Table 1. Baseline demographic and clinical features (n=26)
Feature
Age (yr) 48.2¡11.8
Sex (n, % female) 10 (39)
Ethnicity (n, % minority) 8 (31)
Body mass index (kg/m2) 29.1¡5.9
Received psychiatric disability (n, % yes) 12 (46)
Education (yr) 15.2¡2.7
IQa 114.9¡10.2
Number of adequate antidepressants
trials (median, range)b
6.0¡4.1 (5, 2–18)
Past lamotrigine exposure (n, % yes) 11(42)
Age at ﬁrst major depressive episode (yr) 18.5¡12.2
Duration of index episode (yr) 24.3¡16.3
Ultrachronicc (n, %) 24 (92)
Previous episodes (n) 1.9¡1.7
Comorbid anxiety disorder (n, % yes) 20 (77)
Family history of alcohol use disorder
(n, % yes)
10 (39)
Past alcohol use disorder (n, % yes) 6 (23)
Past substance use disorder (n, % yes) 5 (19)









Expectancy rating patient outcome (1–5) 2.9¡1.0
IDS-C30, Inventory of Depressive Symptoms-Clinician Rated ;
MADRS, Montgomery–Asberg Depression Rating Scale ;
QIDS-SR16, Quick Inventory of Depressive Symptomatology-
Self-Report.
Values are mean¡S.D. unless otherwise indicated.
aWeschler Abbreviated Scale of Intelligence (WASI).
b Antidepressant Treatment History Form, minimum score
of 3 (threshold for classiﬁcation as medication resistant).




















24 h 72 h
Fig. 2. Phase 1 response (%) and remission (&) rates.
Response and remission rates 24-h and 72-h following a
single infusion of intravenous ketamine (0.5 mg/kg over
40 min) in treatment-resistant major depression (n=26),
determined by MADRS and QIDS-SR16.
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group diﬀerences in time-to-relapse (log-rank x2=
0.17, d.f.=1, p=0.68). Mean time-to-relapse for the
riluzole group was 24.4 d (95% CI 15.9–33.0), while
mean time-to-relapse for the placebo group was 22.0 d
(95% CI 14.9–29.1). Among trial completers, 4/5 (80%)
relapsed on riluzole vs. 4/8 (50%) on placebo. Re-
lapsers did not diﬀer from non-relapsers in any char-
acteristic in Table 1. One of six (17%) patients in the
riluzole group met MADRS response criteria at day 32
compared to 4/8 (50%) patients in the placebo group.
MADRS scores at study exit (LOCF) did not diﬀer be-
tween groups (riluzole 20.2¡15.8, placebo 16.5¡11.1 ;
t=x0.51, d.f.=12, p=0.62). Medication dosage at
study exit did not diﬀer signiﬁcantly between groups
(riluzole 116.7¡25.8 mg, placebo 137.5¡23.1 mg; t=
1.59, d.f.=12, p=0.14).
Correlates of outcome
Exploratory analyses revealed that 24-h responders
were signiﬁcantly older (52.4¡10.9 yr) than non-
responders (40.3¡9.6 yr) (t=x2.79, d.f.=24, p=0.01),
and that age was positively correlated with percentage
improvement in 24-h MADRS (r=0.38, p=0.03). Phase
2 participants were older (51.4¡11.5 yr) than non-
participants (44.6¡11.6 yr), although not signiﬁcantly
so (p>0.05). No other demographic or clinical variable
was associated with phase 1 outcome or relapse in
phase 2, including expectancy ratings and psychoto-
mimetic side-eﬀects.
Adverse events
There were no serious adverse events, and no
treatment-emergent mania or suicidality. As expected,
transient increases in mean BP and P were observed
during the ketamine infusion (peak increase in systolic
BP 19.8¡10.1 mmHg, diastolic BP 13.4¡7.7 mmHg;
P 10.9¡11.9 bpm), generally returning to baseline
levels by 40–80 min. There were no clinically mean-
ingful changes in respiratory rate, arterial oxygen
saturation, or ECG. The most commonly reported
side-eﬀects during ketamine infusion and up to 240-
min post-infusion were blurred vision, diminished
mental/sharpness, dizziness/faintness, drowsiness/
sleepiness, feeling strange/unreal, headache, numb-
ness/tingling, ringing in the ears/trouble hearing, and
slurred speech. In phase 2, there were no diﬀerences in
the emergence of moderate-to-severe adverse events
between riluzole and placebo groups (Supplementary
Table S2, online), and no meaningful changes from
baseline in BP, P, weight, or liver function tests.
Integrity of masking
Of patients guessing pretreatment group assignment
in phase 1 (n=23), 14 (60%) guessed correctly, sug-
gesting adequate masking (Fisher’s exact test, p>0.99).
In phase 2, 5/12 patients (42%) correctly guessed their
treatment assignment (Fisher’s exact test, p>0.99),
while the rater correctly guessed assignment for 8/12
patients (67%, Fisher’s exact test, p=0.68.)
Discussion
The main ﬁndings of this study were the following: (1)
65% of TRD patients receiving open-label i.v. keta-
mine at a sub-anaesthetic dose of 0.5 mg/kg met 24-h
response criteria, and 54% showed sustained beneﬁt
for an additional 48 h in the outpatient setting, corro-
borating previous reports (Berman et al. 2000; Zarate
et al. 2006). (2) Riluzole (100–200 mg/d) did not protect
against post-ketamine relapse in the ﬁrst month,
prompting early trial termination. (3) Ketamine, ad-
ministered with or without lamotrigine pretreatment,
was well tolerated. Dissociative symptoms were tran-
sient and generally mild or moderate in severity.
Open-label trial of ketamine
The time-course of antidepressant onset following a
single 40-min infusion of ketamine suggests a rapid
and potentially durable beneﬁt in a majority of
patients. In studies to date in major depression, mood
beneﬁt was detected as early as 2–4 h post-infusion,
after the resolution of acute psychotomimetic side-
eﬀects (Berman et al. 2000 ; Zarate et al. 2006). In the
present study, the majority of patients continued to
meet response criteria 24–72 h following infusion,
a time period extending well beyond ketamine’s






























Fig. 3. Kaplan–Meier survival plot. Cumulative proportion
of patients remaining relapse-free during continuation trial
(phase 2). Log-rank test compared time-to-relapse for
riluzole and placebo groups (x21=0.17, p=0.68.).
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onset has suggested a ‘rebound hypothesis ’, in which
neural compensatory eﬀects are enacted following
acute NMDA receptor blockade (Javitt, 2004). Non-
NMDA receptor targets such as the AMPA glutamate
receptor may be critical to ketamine’s rapid onset
of action (Maeng et al. 2008; Mathew et al. 2008b).
Compounds with AMPA receptor-potentiating pro-
perties have shown antidepressant-like eﬀects in ro-
dents (Black, 2005 ; Knapp et al. 2002 ; Li et al. 2001;
Nakamura & Tanaka, 2001) and AMPA receptor sub-
unit knockout mice demonstrated features of major
depressive disorder (Chourbaji et al. 2008).
A recent pharmaco-magnetic resonance imaging
study in healthy male volunteers found that i.v. keta-
mine (administered by bolus and maintenance in-
fusion of 0.25 mg/kg.h) induced a rapid deactivation
of ventromedial prefrontal cortex (including orbito-
frontal cortex and subgenual cingulate), and increased
activation in dorsolateral prefrontal, middle, and pos-
terior cingulate and temporal cortical regions (Deakin
et al. 2008). Lamotrigine pretreatment prevented many
of the regional blood oxygenation level-dependent
(BOLD) signal changes, and consistent with Anand
et al. (2000), attenuated dissociative symptoms. The
acute pattern of ventromedial deactivation and dorso-
lateral and posterior cingulate activation is similar to
the topographic normalization of brain function fol-
lowing chronic deep brain stimulation in refractory
depression (Mayberg et al. 2005). Pharmaco-MRI stu-
dies are necessary to further develop neural hypo-
theses of i.v. ketamine’s mechanism of action in TRD.
Riluzole continuation trial
We predicted that riluzole, because of its pharmaco-
logical similarities to ketamine, would confer pro-
tection against relapse during the 32-d continuation
trial. Studies in chronic pain disorders have found that
the acute analgesic response to a single low-dose
i.v. ketamine infusion (0.1 mg/kg) strongly correlated
with the subsequent antinociceptive response to oral
dextromethorphan, a low-aﬃnity, non-competitive
NMDA receptor antagonist (Cohen et al. 2004, 2006). In
our TRD sample, the inability of riluzole to maintain
the acute antidepressant response to i.v. ketamine
could be explained by numerous factors, including
diﬀerences in mechanism, route of administration,
and therapeutic dose. Dose–response studies are re-
quired to identify the optimal dose of riluzole for the
acute treatment of depressive symptoms and for the
prevention of relapse.
The durability of the placebo group’s response sug-
gests that beneﬁt following i.v. ketamine administration
may persist for>4 wk in some patients. The durability
of response was especially striking given the magni-
tude of pharmacotherapy resistance in our sample,
and the fact that the entire study was conducted on an
outpatient basis, except for the initial 24-h period. In
the Zarate et al. (2006) in-patient study, six patients
(35%) maintained their response for >1 wk, and two
patients maintained response for >2 wk. Our con-
tinuation trial results are largely consistent with a
pooled analysis that showed persistence of placebo
response in patients who had an acute response
to antidepressant pharmacotherapy and were sub-
sequently switched to placebo (Geddes et al. 2003).
Given the unblinded nature of i.v. ketamine adminis-
tration in phase 1, the confounding impact of initial
placebo response on phase 2 outcome must be con-
sidered. A recent report, for example, showed that
initial placebo responders in double-blind, long-term
eﬃcacy studies have marked persistence of placebo
response if continued on placebo for an additional
12 wk or longer (Khan et al. 2008).
Impact of lamotrigine pretreatment
Contrary to our expectations based on a report in
healthy volunteers (Anand et al. 2000), we did not
observe attenuated psychotomimetic side-eﬀects in
patients randomized to lamotrigine prior to receiving
i.v. ketamine, nor did we ﬁnd a superior antide-
pressant response in patients randomized to lamo-
trigine pretreatment. A key diﬀerence between our
study and the Anand et al. (2000) study was that the
latter used a bolus-constant infusion paradigm with a
higher ketamine dose that produced steady peak keta-
mine plasma levels across the testing period, while we
used a slow ketamine infusion protocol which prob-
ably resulted in briefer exposure to peak ketamine
plasma levels (Krystal et al. 1998). Diﬀerences in sub-
ject characteristics (healthy vs. TRD), and uncertainty
that the loading dose of lamotrigine (300 mg) would
produce the desired pharmacodynamic eﬀect may
also explain contradictions with previous reports
(Anand et al. 2000 ; Deakin et al. 2008). In addition,
processes associated with mood elevation in healthy
volunteers, detected by the YMRS (item 1), probably
diﬀer from reductions in depressive symptoms cap-
tured by depression rating scales in TRD.
The study has several important strengths. (1) It
represents the largest and most medication-resistant
sample of depressed patients treated with i.v. keta-
mine to date. (2) To our knowledge, it is the ﬁrst study
to test response durability and safety on an outpatient
basis. (3) It tested a novel pharmacological strategy
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(lamotrigine pretreatment) to optimize ketamine’s de-
livery in TRD. (4) The continuation trial, while brief in
duration, marks the ﬁrst placebo-controlled investi-
gation of riluzole in mood disorders.
Study limitations
Several methodological limitations are noted. First, the
open-label administration of i.v. ketamine limits de-
ﬁnitive interpretation of phase 1 results. We opted not
to use i.v. saline as a comparator agent because of
limitations in preserving masking due to the negligible
side-eﬀects and lack of eﬃcacy observed in this con-
dition (Berman et al. 2000; Zarate et al. 2006). Future
investigations of i.v. ketamine in TRD should consider
use of an active control comparator arm (e.g. i.v. mid-
azolam, amphetamine, etc.). Second, the sample size
was probably too small to detect moderators and
mediators of response, although the preliminary sug-
gestion of an age association with acute response, with
a positive relationship found between age and 24-h
response, is intriguing. We did not observe a signiﬁ-
cant relationship between treatment resistance and
acute responsiveness to ketamine, consistent with a
recent report exploring moderators of acute ECT out-
come (Rasmussen et al. 2007). Other factors requiring
further study in larger samples include class of pre-
vious psychotropic medication and family or personal
history of alcohol dependence (Petrakis et al. 2004).
Third, regarding the continuation trial, we believe
the marked treatment resistance of the sample justiﬁed
the use of riluzole, despite the lack of placebo-
controlled eﬃcacy data supporting its use in TRD.
While continuation therapy with i.v. ketamine merits
investigation, increased subject burden compared to
oral continuation therapy may limit its application to
the most refractory patients. We also considered con-
tinuation pharmacotherapy with other glutamatergic
agents (e.g. lamotrigine, memantine) but these options
are limited by their slow titration schedules. However,
a recent case report of a patient with severe depression
treated with i.v. ketamine (0.5 mg/kg) found that
subsequent adjunctive treatment with memantine
(dosed at 15 mg/d) prevented relapse for 6 months
(Kollmar et al. 2008), suggesting that this strategy
should be further explored.
Regarding lamotrigine pretreatment, a minimum
sample size of 40 per pretreatment group would have
been necessary to provide 80% power to detect a dif-
ference of 20% in eﬃcacy at 24 h. Thus, the negative
ﬁndings for lamotrigine pretreatment of ketaminemay
possibly be attributed to Type II error. We also did not
obtain blood levels of lamotrigine. This limitation is
somewhat mitigated by patients being psychotropic
medication-free for at least 2 wk prior to infusion;
however, pharmacokinetic diﬀerences in drug meta-
bolism could be relevant. Our study design did not
allow us to compare the lamotrigine/ketamine com-
bination treatment relative to lamotrigine alone ; a
2r2 fully factorial design using an i.v. control group
would be required. Moreover, a single dose of lamo-
trigine may have diﬀerent eﬀects than chronic admin-
istration and may have been insuﬃcient to test the
utility of this approach.
Finally, there are only limited data regarding the
validity of depression rating scales used more fre-
quently than weekly. It is possible that the acute
antidepressant response to i.v. ketamine was under-
estimated due to carrying forward the sleep and
appetite items of the MADRS on the day of infusion.
However, given the open-label nature of the ketamine
administration, we wished to present the most con-
servative estimate of the acute treatment eﬀect.
Further, the primary outcome for the initial phase
of the trial was the 24-h MADRS score, which
included all 10 MADRS items. Instruments such as
the QIDS-SRD14 (modiﬁed for daily use) might oﬀer
greater sensitivity to detect antidepressant eﬀects oc-
curring during time-periods <1 wk than the MADRS
(Lenderking et al. 2008). It is noteworthy that in our
sample the QIDS-SR16 revealed a greater 24-h response
rate than did the MADRS.
Conclusions
These pilot data show that i.v. ketamine is well toler-
ated in TRD, and may have rapid antidepressant
properties. Lamotrigine pretreatment did not inﬂu-
ence the acute eﬃcacy or tolerability of i.v. ketamine.
Given the inevitable relapse of depressive symptoms,
further controlled investigations of interventions that
maintain the initial response, as well as active-control
comparator trials of i.v. ketamine, are required.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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